Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 3, Issue , 2016, Pages 63-72

  Winston, Charisse N ^a   Goetzl, Edward J ^b,c   Akers, Johnny C ^d   Carter, Bob S ^d   Rockenstein, Edward M ^a   Galasko, Douglas ^a   Masliah, Eliezer ^a,d   Rissman, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Biomarker; Exosomes; Mild cognitive impairment; Neuron; Phospho tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; NEUROGRANIN; REPRESSOR ELEMENT 1 SILENCING TRANSCRIPTION FACTOR; TAU PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; HIPPOCAMPAL CA1 REGION; HUMAN; IMMUNOHISTOCHEMISTRY; MILD COGNITIVE IMPAIRMENT; MOUSE; NANOSIGHT SYSTEM; NONHUMAN; OPTICAL INSTRUMENTATION; PREDICTION; PREDICTIVE VALUE; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84975514611     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2016.04.001     Document Type: Article

References (48)

1. Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013, 80:1778-1783.
2. Ward A., Arrighi H.M., Michels S., Cedarbaum J.M. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement 2012, 8:14-21.
3. Grundman M., Petersen R.C., Ferris S.H., Thomas R.G., Aisen P.S., Bennett D.A., et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004, 61:59-66.
4. van Rossum I.A., Vos S., Handels R., Visser P.J. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010, 20:881-891.
5. Parnetti L., Farotti L., Eusebi P., Chiasserini D., De Carlo C., Giannandrea D., et al. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. Front Aging Neurosci 2014, 6:53.
6. Lanari A., Parnetti L. Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting. ScientificWorldJournal 2009, 9:961-966.
7. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
8. Agarwal R., Tripathi C.B. Diagnostic Utility of CSF Tau and Abeta(42) in Dementia: A Meta-Analysis. Int J Alzheimers Dis 2011, 2011:503293.
9. Andreasson U., Lautner R., Schott J.M., Mattsson N., Hansson O., Herukka S.K., et al. CSF biomarkers for Alzheimer's pathology and the effect size of APOE varepsilon4. Mol Psychiatry 2014, 19:148-149.
10. Zetterberg H., Lautner R., Skillback T., Rosen C., Shahim P., Mattsson N., et al. CSF in Alzheimer's disease. Adv Clin Chem 2014, 65:143-172.
11. Mattsson N., Insel P.S., Landau S., Jagust W., Donohue M., Shaw L.M., et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol 2014, 1:534-543.
12. Rosen C., Hansson O., Blennow K., Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener 2013, 8:20.
13. Rosen C., Rosen H., Andreasson U., Bremell D., Bremler R., Hagberg L., et al. Cerebrospinal fluid biomarkers in cardiac arrest survivors. Resuscitation 2014, 85:227-232.
14. Rosen C., Zetterberg H. Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. Curr Opin Psychiatry 2013, 26:276-282.
15. Okamura N., Harada R., Furumoto S., Arai H., Yanai K., Kudo Y. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep 2014, 14:500.
16. Fiandaca M.S., Kapogiannis D., Mapstone M., Boxer A., Eitan E., Schwartz J.B., et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement 2015, 11:600-607.e1.
17. Kapogiannis D., Boxer A., Schwartz J.B., Abner E.L., Biragyn A., Masharani U., et al. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. FASEB J 2015, 29:589-596.
18. Goetzl E.J., Boxer A., Schwartz J.B., Abner E.L., Petersen R.C., Miller B.L., et al. Low neural exosomal levels of cellular survival factors in Alzheimer's disease. Ann Clin Transl Neurol 2015, 2:769-773.
19. Goetzl E.J., Boxer A., Schwartz J.B., Abner E.L., Petersen R.C., Miller B.L., et al. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology 2015, 85:40-47.
20. Simons M., Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009, 21:575-581.
21. Théry C., Amigorena S., Raposo G., Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006, Chapter 3:Unit 3.22.
22. Rajendran L., Honsho M., Zahn T.R., Keller P., Geiger K.D., Verkade P., et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 2006, 103:11172-11177.
23. Budnik V., Ruiz-Cañada C., Wendler F. Extracellular vesicles round off communication in the nervous system. Nat Rev Neurosci 2016, 17:160-172.
24. Vingtdeux V., Hamdane M., Loyens A., Gele P., Drobeck H., Begard S., et al. Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. J Biol Chem 2007, 282:18197-18205.
25. Davidsson P., Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr 1998, 10:11-23.
26. Kester M.I., Teunissen C.E., Crimmins D.L., Herries E.M., Ladenson J.H., Scheltens P., et al. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. JAMA Neurol 2015, 72:1275-1280.
27. Portelius E., Zetterberg H., Skillbäck T., Törnqvist U., Andreasson U., Trojanowski J.Q., et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain 2015, 138:3373-3385.
28. Ingelsson M., Fukumoto H., Newell K.L., Growdon J.H., Hedley-Whyte E.T., Frosch M.P., et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004, 62:925-931.
29. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
30. Chang J.W., Schumacher E., Coulter P.M., Vinters H.V., Watson J.B. Dendritic translocation of RC3/neurogranin mRNA in normal aging, Alzheimer disease and fronto-temporal dementia. J Neuropathol Exp Neurol 1997, 56:1105-1118.
31. Kvartsberg H., Duits F.H., Ingelsson M., Andreasen N., Öhrfelt A., Andersson K., et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement 2015, 11:1180-1190.
32. Chong J.A., Tapia-Ramírez J., Kim S., Toledo-Aral J.J., Zheng Y., Boutros M.C., et al. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 1995, 80:949-957.
33. Coulson J.M. Transcriptional regulation: cancer, neurons and the REST. Curr Biol 2005, 15:R665-R668.
34. Lu T., Aron L., Zullo J., Pan Y., Kim H., Chen Y., et al. REST and stress resistance in ageing and Alzheimer's disease. Nature 2014, 507:448-454.
35. Burghardt R.C., Droleskey R. Transmission electron microscopy. Curr Protoc Microbiol 2006, Chapter 2:Unit 2B.1.
36. Mitsuhashi M., Taub D.D., Kapogiannis D., Eitan E., Zukley L., Mattson M.P., et al. Aging enhances release of exosomal cytokine mRNAs by Abeta1-42-stimulated macrophages. FASEB J 2013, 27:5141-5150.
37. Campbell S.N., Zhang C., Monte L., Roe A.D., Rice K.C., Tache Y., et al. Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor. J Alzheimers Dis 2015, 43:967-976.
38. Shu S.Y., Ju G., Fan L.Z. The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system. Neurosci Lett 1988, 85:169-171.
39. van der Pol E., Coumans F.A., Grootemaat A.E., Gardiner C., Sargent I.L., Harrison P., et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost 2014, 12:1182-1192.
40. Laske C., Sohrabi H.R., Frost S.M., López-de-Ipiña K., Garrard P., Buscema M., et al. Innovative diagnostic tools for early detection of Alzheimer's disease. Alzheimers Dement 2015, 11:561-578.
41. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13:1359-1362.
42. Soares H.D., Chen Y., Sabbagh M., Roher A., Rohrer A., Schrijvers E., et al. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 2009, 1180:56-67.
43. Sparks D.L., Kryscio R.J., Sabbagh M.N., Ziolkowski C., Lin Y., Sparks L.M., et al. Tau is reduced in AD plasma and validation of employed ELISA methods. Am J Neurodegener Dis 2012, 1:99-106.
44. Alvarez-Erviti L., Seow Y., Schapira A.H., Gardiner C., Sargent I.L., Wood M.J., et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 2011, 42:360-367.
45. Shi M., Liu C., Cook T.J., Bullock K.M., Zhao Y., Ginghina C., et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol 2014, 128:639-650.
46. Fevrier B., Vilette D., Archer F., Loew D., Faigle W., Vidal M., et al. Cells release prions in association with exosomes. Proc Natl Acad Sci U S A 2004, 101:9683-9688.
47. Grad L.I., Pokrishevsky E., Silverman J.M., Cashman N.R. Exosome-dependent and independent mechanisms are involved in prion-like transmission of propagated Cu/Zn superoxide dismutase misfolding. Prion 2014, 8:331-335.
48. Stern R.A., Tripodis Y., Baugh C.M., Fritts N.G., Martin B.M., Chaisson C., et al. Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy. J Alzheimers Dis 2016, 10:1099-1109.